We design each project around the decision it must support: R&D, partner discussion, investor diligence, regulatory planning, or product development.
Our services are organized around the capabilities that make a program credible: fit-for-purpose reagents, reproducible assays, analytical performance, and clear technical communication.
We develop and optimize assays for low-abundance proteins, complex matrices, and early translational biomarkers.
High-performance assays need reagents selected for application, not only binding.
For programs that need sensitivity beyond standard colorimetric ELISA, we support antibody-oligo and qPCR-compatible immunoassay concepts.
We help turn experimental work into materials that external stakeholders can understand, evaluate, and act on.
Most complex programs should start with stage-gated work that creates useful evidence at each step.
Target biology, sample type, intended use, decision point, and success criteria.
Reagents, matrix behavior, signal window, and practical constraints.
Conditions, buffers, standards, controls, and reproducibility.
Analytical performance appropriate for the project stage.
Technical narrative, data summary, and next-step plan.
For more specific project needs, these pages outline common service paths and the details that help us scope work quickly.
Assay design, antibody pairing, optimization, and validation planning for biomarker programs.
Analytical performance planning, matrix evaluation, reproducibility, and scientific package support.
High-sensitivity protein readout planning, antibody-oligo conjugation, and qPCR-compatible workflows.
Antibody pairing, recombinant antigen strategy, raw material qualification, and assay-ready reagent support.
Assay credibility, translational positioning, and U.S.-facing scientific package development.
Pricing and timelines depend on target complexity, reagent availability, matrix, validation requirements, and project stage.
| Program | Typical Scope | Best For | Typical Turnaround |
|---|---|---|---|
| ELISA feasibility | Pairing, signal window, matrix check, preliminary sensitivity | Deciding whether a target or reagent set is worth deeper development | 2-4 weeks |
| Antibody pairing | Clone evaluation, capture/detection pairing, cross-reactivity checks | Building a functional sandwich assay | 1-3 weeks per target |
| Assay optimization | Linearity, precision, dynamic range, matrix, buffers, controls | Turning feasibility into reproducible assay performance | 2-4 weeks |
| Translational package | Validation plan, data summary, U.S.-facing technical narrative | Partner, investor, BD, or regulatory-facing discussion | 1-3 weeks after data availability |
These areas connect directly to the strategic capabilities highlighted on the homepage.
Support for plasma/CSF biomarkers including tau-related targets, NfL, GFAP, and neurodegeneration panels.
Feasibility, conjugation, control design, and planning for qPCR-compatible protein readouts.
Recombinant proteins, antibody reagents, calibrators, controls, and raw materials for assay development.
Send the target, sample type, current reagent status, and timeline, and we will suggest a practical next step.
Request a Quote